Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Vertex Pharmaceuticals Incorporated < Previous 1 2 3 4 Next > European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5 November 23, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia November 16, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers CRSP VRTX Vertex Reports Third Quarter 2023 Financial Results November 06, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition November 02, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference November 02, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present at Upcoming Investor Conferences October 26, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce Third Quarter 2023 Financial Results on November 6 October 10, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Appoints Michel Lagarde to its Board of Directors October 05, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting October 03, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5 September 15, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences September 14, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13 August 30, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations August 29, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine August 03, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports Second Quarter 2023 Financial Results August 01, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce Second Quarter 2023 Financial Results on August 1 June 30, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies June 26, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions June 23, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference June 09, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress June 09, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers CRSP VRTX FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia June 08, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers CRSP VRTX Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13 May 30, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older May 03, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports First Quarter 2023 Financial Results May 01, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations April 26, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9 April 25, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce First Quarter 2023 Financial Results on May 1 April 10, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia April 03, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers CRSP VRTX Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes March 27, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers CRSP VRTX Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147) March 16, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.